SHIFA BIOMEDICAL CORPORATION
Chitosan and methylated chitosan nanoformulations for extraction, solubilization, and stabilization of bioactive natural products from plant sources
- Sector
- Biotech
- Headquarters
- Malvern, PA
- Latest Form D
- $1.8M, May 2021
- Total capital
- $8.2M
- Federal grants
- $6.4M
- 8 awards · 2015–2025
- Rank in peer group#4 of 20
- Private capital raised
- $1.8M
- 1 Form D · last May 2021
- 65 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 9 pending · first 2017
- Rank in peer group#5 of 20
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Executing the IND-Enabling Studies for Oral PCSK9/LDLR antagonist$1.2M
- Federal grantHealth and Human S · Phase II · Executing the IND-Enabling Studies for Oral PCSK9/LDLR antagonist$1.3M
- Private capital raisedForm D · SEC · 1st filing$1.8M
- Federal grantHealth and Human S · Phase II · Oral PCSK9/LDLR antagonist direction to the clinic$945K
- Federal grantHealth and Human S · Phase II · Oral PCSK9/LDLR antagonist direction to the clinic$944K
- Federal grantHealth and Human S · Phase I · Improving Solubility, Stability and Permeability of Natural Products Extracts$287K
- Federal grantHealth and Human S · Phase II · Development of Oral Small Molecule PCSK9 Antagonist$667K
Show 2 earlier federal awards
- Federal grantHealth and Human S · Phase II · Development of Oral Small Molecule PCSK9 Antagonist$682K
- Federal grantHealth and Human S · Phase II · Novel Modulators of LDL Metabolism$500K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
73months
from SHIFA BIOMEDICAL CORPORATION’s first federal award to its first private round.
- First federal award · Apr 2015
- Health and Human S · $500K
- First Form D · May 2021
- $1.8M · 1st Form D
- Awards before first raise
- 6 awards
An association in public records, not a cause or a prediction.
Standing among 20 peers
Line = medianBiotech · Material
- Federal grants#4 · top 20%
- Granted patents#5 · top 25%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Shaker S. MousaResearcherDirectorLinked by 1 patent
- Chris S. GarabedianDirectorNamed in SEC Form D filings
- Gianna S. Hoffman-LucaDirectorNamed in SEC Form D filings
- Sherin S. Abdel-Meguid, Ph.D.Executive Officer, DirectorNamed in SEC Form D filings
- Tarik S. Abdel-MeguidExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 14- GrantedAnti-proprotein Convertase Subtilisin Kexin Type 9 (ANTI-PCSK9) Nano-formulation Of Compounds And Methods Of Using The SameUSPTOUS 12,274,693
- GrantedAnti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular DiseasesUSPTOUS 10,947,220
- GrantedAnti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular DiseasesUSPTOUS 10,899,748
Show all 14 patent records
- Anti-proprotein Convertase Subtilisin Kexin Type 9 (ANTI-PCSK9) Nano-formulation Of Compounds And Methods Of Using The SameApr 15, 2025 · US 12,274,693Granted
- Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular DiseasesMar 16, 2021 · US 10,947,220Granted
- Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular DiseasesJan 26, 2021 · US 10,899,748Granted
- Anti-endothelial Lipase Compounds And Methods Of Using The Same In The Treatment And/or Prevention Of Cardiovascular DiseasesApr 16, 2019 · US 10,259,804Granted
- ANTI-PCSK9 Compounds And Methods For The Treatment And/or Prevention Of Cardiovascular DiseasesMar 22, 2018 · Application 15829028Pending
- Anti-proprotein Convertase Subtilisin Kexin Type 9 (ANTI-PCSK9) Compounds And Methods Of Using The Same In The Treatment And/or Prevention Of Cardiovascular DiseasesJun 20, 2017 · US 9,682,085Granted
- Functionalized FURAN-2-SULFONAMIDES Exhibiting Endothelial Lipase InhibitionSep 8, 2016 · Application 15028164Pending
- Anti-proprotein Convertase Subtilisin Kexin Type 9 (ANTI-PCSK9) Compounds And Methods Of Using The Same In The Treatment And/or Prevention Of Cardiovascular DiseasesSep 8, 2016 · Application 15152703Pending
- Anti-proprotein Convertase Subtilisin Kexin Type 9 (ANTI-PCSK9) Compounds And Methods Of Using The Same In The Treatment And/or Prevention Of Cardiovascular DiseasesApplication PCTUS2014023135Pending
- Anti-proprotein Convertase Subtilisin Kexin Type 9 (ANTI-PCSK9) Nano-formulation Of Compounds And Methods Of Using The Same In The Treatment And/or Prevention Of Cardiovascular DiseasesApplication PCTUS2019059777Pending
- Anti-proprotein Convertase Subtilisin Kexin Type 9 (ANTI-PCSK9) Compounds And Methods Of Using The Same In The Treatment And/or Prevention Of Cardiovascular DiseasesApplication PCTUS2017038069Pending
- Antithrombotic TherapiesApplication PCTUS2016036646Pending
- Anti-endothelial Lipase Compounds And Methods Of Using The Same In The Treatment And/or Prevention Of Cardiovascular DiseasesApplication PCTUS2015051630Pending
- Anti-proprotein Convertase Subtilisin Kexin Type 9 (ANTI-PCSK9) Compounds And Methods Of Using The Same In The Treatment And/or Prevention Of Cardiovascular DiseasesApplication PCTUS2014022957Pending
Related companies, and why
- Theratome Bio, Inc.Similar federal contract value in Biotech · null in contracts
- Blue Oak Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- BasisSimilar federal contract value in Biotech · null in contracts
- MDI THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- NOVILYTIC, LLCSimilar federal contract value in Biotech · null in contracts
- OPTIKIRA, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .